Oil Prices Set for Sharp Weekly Losses as U.S.-Iran Ceasefire Hopes Ease Supply Concerns 
South Korea Central Bank Holds Interest Rates Steady Amid Inflation Concerns 
S&P 500 Hits Record High as Tech Rally Slows Amid Iran Peace Uncertainty 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Tokyo Inflation Cools in May, Supporting BOJ’s Cautious Rate Hike Path 
US Dollar Slips as Markets Weigh Potential US-Iran Peace Deal and Oil Price Outlook 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Iran-U.S. Nuclear Talks Remain Unresolved as Strait of Hormuz Risks Keep Markets on Edge 
Canada and Germany Advance Major LNG Supply Partnership 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
US Imposes Fresh Iran Oil Sanctions Despite Progress on Ceasefire Talks 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
BCA Research Warns Iran and Ukraine Ceasefires May Offer Limited Relief for Global Markets 
Asian Currencies Steady as U.S.-Iran Ceasefire Extension Hopes Weigh on Dollar 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
